The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available that are not considered orphan products.

• Cladribine (Brand name: Leustatin (injection)) - Manufactured by Ortho Biotech
  FDA-approved indication: Treatment of hairy cell leukemia.
  National Library of Medicine Drug Information Portal Medline Plus Health Information

  Learn more about Hairy cell leukemia

• Moxetumomab pasudotox (Brand name: Lumoxiti) - Manufactured by AstraZeneca Pharmaceuticals LP
  FDA-approved indication: September 2018, moxetumomab pasudotox (Lumoxiti) was approved for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
  National Library of Medicine Drug Information Portal

  Learn more about Hairy cell leukemia

• Pentostatin for injection (Brand name: Nipent®) - Manufactured by SuperGen, Inc.
  FDA-approved indication: Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.
  National Library of Medicine Drug Information Portal Medline Plus Health Information

  Learn more about Hairy cell leukemia